Biomedicines (Aug 2023)

HSP47: A Therapeutic Target in Pulmonary Fibrosis

  • Noriho Sakamoto,
  • Daisuke Okuno,
  • Takatomo Tokito,
  • Hirokazu Yura,
  • Takashi Kido,
  • Hiroshi Ishimoto,
  • Yoshimasa Tanaka,
  • Hiroshi Mukae

DOI
https://doi.org/10.3390/biomedicines11092387
Journal volume & issue
Vol. 11, no. 9
p. 2387

Abstract

Read online

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by a progressive decline in lung function and poor prognosis. The deposition of the extracellular matrix (ECM) by myofibroblasts contributes to the stiffening of lung tissue and impaired oxygen exchange in IPF. Type I collagen is the major ECM component and predominant collagen protein deposited in chronic fibrosis, suggesting that type I collagen could be a target of drugs for fibrosis treatment. Heat shock protein 47 (HSP47), encoded by the serpin peptidase inhibitor clade H, member 1 gene, is a stress-inducible collagen-binding protein. It is an endoplasmic reticulum-resident molecular chaperone essential for the correct folding of procollagen. HSP47 expression is increased in cellular and animal models of pulmonary fibrosis and correlates with pathological manifestations in human interstitial lung diseases. Various factors affect HSP47 expression directly or indirectly in pulmonary fibrosis models. Overall, understanding the relationship between HSP47 expression and pulmonary fibrosis may contribute to the development of novel therapeutic strategies.

Keywords